Wall Street analyst estimates for Agenus Inc. (AGEN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies.
Valuation Ratios
| P/E Ratio | 2.68 |
| Price / Book | -1.51 |
| EV / EBITDA | 2.34 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.6M | $42.9M | $36.8M | $150.0M | $88.2M | $295.7M | $98.0M | $156.3M | $103.5M | $114.2M |
| Cost of Revenue | $95.0M | $116.1M | $124.6M | $168.3M | $145.0M | $182.1M | $197.3M | $237.7M | $156.0M | $80.4M |
| Gross Profit | -$72.4M | -$73.2M | -$87.8M | -$18.3M | -$56.8M | $113.6M | -$99.2M | -$81.4M | -$52.6M | $33.8M |
| Research & Development | $95.0M | $116.1M | $124.6M | $168.3M | $142.6M | $178.6M | 0 | $234.6M | $155.5M | 0 |
| Selling, General & Admin | $33.1M | $33.7M | $37.3M | $46.0M | $59.2M | $76.4M | $81.0M | $78.7M | $71.9M | $54.4M |
| Operating Expenses | $33.1M | $33.7M | $37.3M | $51.8M | $60.4M | $87.8M | $80.2M | $78.2M | $67.9M | $54.4M |
| Operating Income | -$107.5M | -$103.8M | -$123.8M | -$70.1M | -$117.2M | $25.7M | -$179.4M | -$159.5M | -$120.5M | -$20.6M |
| EBITDA | -$104.7M | -$95.8M | -$130.5M | -$63.4M | -$114.6M | $43.8M | -$161.8M | -$145.9M | -$101.3M | $62.2M |
| Interest Expense | $17.3M | $18.9M | $25.3M | $41.5M | $61.1M | $65.7M | $61.9M | $97.9M | $117.6M | $55.3M |
| Pre-tax Income | -$127.0M | -$120.7M | -$162.0M | -$111.6M | -$182.9M | -$28.7M | -$230.7M | -$257.4M | -$232.3M | -$3.1M |
| Income Tax | -$3.0M | 0 | -$12.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$127.0M | -$120.7M | -$159.7M | -$107.7M | -$180.9M | -$23.9M | -$220.1M | -$245.8M | -$227.2M | $115000 |
| EPS | $-29.17 | $-24.53 | $-28.83 | $-22.10 | $-21.00 | $-2.11 | $-15.64 | $-13.75 | $-10.59 | $-0.00 |
| EPS (Diluted) | $-29.17 | $-24.53 | $-28.83 | $-22.10 | $-21.00 | $-2.11 | $-15.64 | $-13.75 | $-10.59 | $-0.00 |
| Shares Outstanding (Diluted) | $4.4M | $4.9M | $5.5M | $6.7M | $8.6M | $11.4M | $14.1M | $17.9M | $21.5M | $29.7M |
Price
| Price | $7.21 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · FATE · HURA · INO · IRD · PLRX · SEER
Explore sector: Healthcare · Biotechnology
More sections of AGEN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks